SCHEMBL4096702

SCHEMBL4096702

Oc1cc(-c2[nH]c(=S)[nH]c2-c2ccc(F)cc2)ccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 3/20 0.44
HPGD P15428 2/20 0.44
GFER P55789 1/20 0.44
MAPK13 O15264 5/20 0.40
MAPK12 P53778 5/20 0.40
MAPK11 Q15759 5/20 0.40
GCGR P47871 4/20 0.40
RAF1 P04049 2/20 0.39
MAPK9 P45984 2/20 0.39
ALOX5 P09917 2/20 0.39
KDM4E B2RXH2 1/20 0.39
CIT O14578 1/20 0.39
GAK O14976 1/20 0.39
RIPK2 O43353 1/20 0.39
BRD4 O60885 1/20 0.39
GMNN O75496 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL828544 0.84 MAPK14 (0.55) MAPK14ALDH1A1MAPTHPGDGFER
SCHEMBL4472359 0.82 MAPK14 (0.55) MAPK14ALDH1A1MAPTHPGDGFER
SCHEMBL1150867 0.79 MAPK14 (0.68) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL828252 0.78 MAPK14 (0.55) MAPK14MAPK13MAPK12MAPK11EGFR
SCHEMBL4462969 0.78 MAPK14 (0.59) MAPK14ALDH1A1MAPTHPGDGFER
SCHEMBL11180564 0.78 ALDH1A1 (0.50) MAPK14ALDH1A1MAPTHPGDGFER
SCHEMBL4466663 0.75 MAPK14 (0.61) MAPK14ALDH1A1MAPTHPGDGFER
SCHEMBL828605 0.75 MAPK14 (0.53) MAPK14MAPK13MAPK12MAPK11
SCHEMBL828385 0.75 MAPK14 (0.65) MAPK14MAPK10
SCHEMBL828379 0.74 MAPK14 (0.78) MAPK14MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 US disclosed
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 US disclosed
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 US disclosed
US-20060106020-A1 Tetracyclic inhibitors of Janus kinases INCYTE CORPORATION 2006-05-18 US disclosed
WO-2005105814-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION (US) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES JAK1, JAK2, JAK3 MAPK14 136/4885ALDH1A1 3857/4885MAPT 2554/4885
US-20060106020-A1 Tetracyclic inhibitors of Janus kinases JAK1, JAK2, JAK3 MAPK14 136/4885ALDH1A1 3857/4885MAPT 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.